Identification and prediction of neoantigens forms the basis of effective individualised therapies in this space. The implementation and constant development of bioinformatics approaches underpins this process, and must interrogate a number of key areas to guarantee effectiveness:
• Prediction of mutated peptides and peptide immunogenicity
• MHC class I and MHC class II ligands and epitopes
• Rational epitope discovery
• Analysing data from matched tumours and normal samples
• Selection of expressed peptides by integrating HLA typing
This workshop provides you with a comprehensive view of all the techniques and technologies currently being used to develop neoantigen-based therapies. Leave this session with the information you need to ensure you are using the most up to date, efficient, accurate and reliable processes.
Workshop Leader: Morten Nielsen, Professor, Group Leader, Immunoinformatics and Machine-Learning, Center for Biological Sequence Analysis, The Technical University of Denmark
The manufacture of individualised therapies presents a huge logistical challenge and requires a complete overhaul of current systems. This session provides a detailed insight into upscaling the manufacture of individualised cancer vaccine to meet market demand:
• Key considerations when manifesting therapies centred
around each of the prevalent modalities
• Manufacturing individualised therapies at scale
• What steps can be taken to ensure that your neoantigen
based therapy is affordable?
• Cost-effective methods for sourcing key materials
• Strategy alterations for combination therapies
This workshop highlights the key areas of manufacturing for neoantigen vaccines. Leave the session with actionable insights for the planning, implementation and maintenance of manufacturing strategies for personalised cancer vaccines.
Workshop Leaders: Agnete Fredriksen, CSO, Vaccibody – Matthias Miller, Senior Project Manager, BioNTech – Andrea van Elsas, CSO, Aduro Biotech